<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211509</url>
  </required_header>
  <id_info>
    <org_study_id>MLK002</org_study_id>
    <nct_id>NCT01211509</nct_id>
  </id_info>
  <brief_title>Montelukast in Bronchiolitis Obliterans Syndrome</brief_title>
  <acronym>MLK002</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic rejection (or Bronchiolitis Obliterans syndrome-BOS) is a major cause of mortality
      and morbidity after lung transplantation. Because montelukast has been shown to be of some
      efficacy in a similar disease (Obliterative Bronchiolitis after bone marrow transplantation),
      the investigators would like to test if montelukast can indeed slow down the progression of
      chronic rejection after lung transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, interventional, randomized, double-blind, placebo-controlled trial.

        -  Clinical setting (tertiary University Hospital).

        -  Investigator-driven, no pharmaceutical sponsor.

        -  Lung transplant recipients.

        -  Add-on of study-drug (placebo or montelukast) to 'standard of care'

        -  1:1 inclusion ratio (placebo:montelukast).

        -  Randomisation at diagnosis of chronic rejection after informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival/retransplantation rate after diagnosis of BOS</measure>
    <time_frame>1 year after diagnosis</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>survival/retransplantation rate at 2 years after diagnosis</measure>
    <time_frame>2 years after diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obstructive and restrictive pulmonary function evolution</measure>
    <time_frame>during 1 and 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar lavage fluid (BAL)</measure>
    <time_frame>during 1 and 2 years of treatment</time_frame>
    <description>BAL will be used to assess cellularity, protein and mRNA concentration and microbiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral blood</measure>
    <time_frame>during 1 and 2 years of treatment</time_frame>
    <description>peripheral blood will be used to assess C-reactive protein, protein and mRNA concentration and fibrocytes content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytomegalovirus (CMV) and non-CMV infection rates</measure>
    <time_frame>during 1 and 2 years of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection and lymphocytic bronchiolitis rates</measure>
    <time_frame>after 1 and 2 years of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Lung Transplantation</condition>
  <condition>Graft Rejection</condition>
  <arm_group>
    <arm_group_label>montelukast sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose monohydricum Ph.Eur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo</description>
    <arm_group_label>montelukast sodium</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Montelukast TEVA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of fBOS

          -  Signed informed consent

          -  Age at least 18 years old at moment of transplantation

          -  Able to take oral medication

        Exclusion Criteria:

          -  Retransplantation

          -  Previous organ transplantation

          -  Multi organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert M Verleden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, Sacks Z, Shapira MY. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation. 2007 Mar 15;83(5):577-81.</citation>
    <PMID>17353777</PMID>
  </reference>
  <reference>
    <citation>Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008 Oct;32(4):832-43. doi: 10.1183/09031936.00134307. Review.</citation>
    <PMID>18827151</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Geert Verleden</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>montelukast</keyword>
  <keyword>cysteinyl leukotriene</keyword>
  <keyword>lung transplantation</keyword>
  <keyword>bronchiolitis obliterans syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

